Exiqon
Home Search Contact Print Mobile Sign In
 
 
Products Services Applications Resource Center Ordering About Exiqon Investor
microRNA Research
RNA Research
DNA Research
Custom Oligos
Other Reagents
RNA Isolation
Microarray Analysis
Real-time PCR
Northern Blotting
In Situ Hybridization
Functional Analysis
RNA Preparation
Microarray analysis
Real-time PCR
In Situ Hybridization
Antisense
SNP Detection
Microarray Analysis
In Situ Hybridization
LNA Phosphoramidites
AQ-link Products
A2 Quencher
RNA Isolation Services
microRNA Array Services
microRNA PCR Services
microRNA ISH Services
Isolation
Microarray Analysis
Northern Blotting
Real-time PCR
In Situ Hybridization
Functional Analysis
SNP Detection
RNA
microRNA
RNA
DNA
microRNA
microRNA
mRNA
microRNA
Other RNAs
DNA
microRNA
RNA
DNA
MicroRNA Research
RNA Research
Other reagents
Technology Base
Oligo design tools
Exiqon E-talk
Research Guide
Array Downloads
qPCR Data Analysis
Technical Literature and Manuals
Scientific Publications
Application Stories
Bioinformatics
Technical Literature and Manuals
Scientific Publications
Application Stories
Bioinformatics
Technical Literature and Manuals
Scientific Publications
Oligo modifications
LNA™
AQ-link
Order microRNA products
Order custom oligos
Distributors
General Information
Contact
Company profile
Sign up to Newsletter
Newsletter Back Issues
Investor Relations
Media
Announcements
Financials
Guidelines for Incentive Pay
Corporate Governance
Investor Signup
Contact Us
Share Info
Calendar
Reports
Figures
Analysts
Presentations
Contact
Tal og fakta
Samarbejdspartnere
IR Policy
Articles of Association
 
EN
DK
 
Announcements
05 January 2012 PressRelease_GrantProgram_120105.pdf
Exiqon A/S - Exiqon Announces 2012 Grant Program for MicroRNA Research
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”), a leading supplier of high-value products for gene expression analysis, today announced the launch of its 2012 global research grant program, open to researc ...
30 December 2011 Announcement_29_2011_Sharecapitalandvotingrights.pdf
Exiqon A/S - Exiqon A/S’ share capital and total number of voting rights
Pursuant to Section 6 of executive order no. 220 of 10 March 2010 about issuers' disclosure obligations, it is hereby announced that Exiqon A/S' entire share capital on 30 December 2011 is DKK 35,069, ...
08 December 2011 Announcement_28_2011_Warrants.pdf
Exiqon A/S - Exiqon A/S increases its share capital in connection with exercise of warrants
Exiqon A/S has today 8 December 2011 completed an increase of its share capital by DKK 67,000, nominal value, as a result of an exercise of warrants. The increase of the share capital is expected to b ...
22 November 2011 Announcement_27_2011_warrants_v2.pdf
Exiqon A/S - Exiqon A/S Report regarding the management's and closely related parties' transactions with securities in Exiqon A/S
Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) hereby announces the management's and their closely related parties' transactions with shares an ...
10 November 2011 Announcement_26_Q3_2011.pdf
Exiqon A/S - INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 SEPTEMBER 2011 (UNAUDITED)
Reported figures are for the full reporting period unless otherwise stated. Figures for the comparable reporting period last year is stated in parenthesis after realized figures. Comparative numbers i ...
10 November 2011 Announcement_25_2011_Financial_Calendar_2012.pdf
Exiqon A/S - Exiqon A/S announces financial calendar for 2012
Below are the expected dates for Exiqon A/S' annual general meeting and financial reporting in 2012. Financial calendar Deadline for shareholders' proposal to the annual general 14 February 2 ...
27 October 2011 Announcement_Oct2011_ASCO_EORTC_final.pdf
Exiqon A/S - Exiqon validates blood plasma-based miRNA PCR test for early detection of colorectal cancer
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the presentation of data at the 2011 EORTC-NCI-ASCO meeting in Brussels providing initial validation of the company's blood plasma-based miRNA ...
12 October 2011 PressRelease_Oct2011_Inhibitors.pdf
Exiqon A/S - Exiqon introduces new products for functional analysis of microRNA families
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for gene expression analysis, today announced the launch of its miRCURY LNA™ microRNA Family Inhibitors for efficient inactivati ...
10 October 2011 PressRelease_Oct_RD_products.pdf
Exiqon A/S - Exiqon launches new products for the research and development of LNA™ based drugs
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for gene expression analysis, today announced the expansion of its product offering to include LNA™ products for the research an ...
07 October 2011 Announcement_23_2011_litigation_completed.pdf
Exiqon A/S - Exiqon A/S completes litigation against Santaris Pharma a/s
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that the company has completed its litigation against Santaris Pharma a/s. In 2010, Exiqon initiated arbitration proceedings to defend its b ...
Investor signup

Exiqon Investor Portal

Register your email
Exiqon uses electronic communication with our shareholders. We therefore kindly ask you to register your email address in Exiqon’s investor portal. You will then receive notices convening annual and extraordinary general meetings by email.
You log in to the investor portal by using your net-ID from your net bank or by using your VP logon. If you do not have a VP logon already, simply click “Create VP-user" to order one.
Visit the Exiqon Investor Portal
Information on Exiqon’s other activities and news
If you wish to receive other news from Exiqon, e.g. press releases, announcements and annual reports, please sign-up here:
Signup to receive investor news
  Privacy   Sitemap   Legal